A.R.T. Advisors’s Coherus Oncology CHRS Stock Holding History

A.R.T. Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-83,343	Closed	-$1.5M	–	223
2019 Q4	$1.5M	Buy	83,343 +44,900	+117%	+$828K	0.07%	407
2019 Q3	$779K	Sell	38,443 -51,300	-57%	-$1.02M	0.04%	665
2019 Q2	$1.98M	Sell	89,743 -13,200	-13%	-$229K	0.11%	237
2019 Q1	$1.4M	Buy	+102,943	New	+$1.37M	0.08%	352
2018 Q4	–	Sell	-75,440	Closed	-$1.24M	–	1354
2018 Q3	$1.24M	Buy	75,440 +42,500	+129%	+$753K	0.06%	483
2018 Q2	$461K	Buy	32,940 +8,695	+36%	+$124K	0.02%	956
2018 Q1	$267K	Buy	+24,245	New	+$265K	0.01%	1175
2017 Q4	–	Sell	-13,099	Closed	-$174K	–	1401
2017 Q3	$174K	Buy	+13,099	New	+$173K	0.01%	1157
2017 Q1	–	Sell	-33,400	Closed	-$940K	–	1450
2016 Q4	$940K	Buy	33,400 +24,900	+293%	+$697K	0.06%	504
2016 Q3	$227K	Buy	+8,500	New	+$232K	0.07%	446

Other funds holding CHRS

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

A.R.T. Advisors's CHRS Position: Q1 2020 in Review

A.R.T. Advisors sold out of Coherus Oncology (CHRS) in Q1 2020, closing a stake of 83,343 shares — an estimated $1.5M sold.

A.R.T. Advisors first reported a position in CHRS in Q3 2016 and held it in 10 quarters. The position peaked at $1.98M in Q2 2019. 186 funds tracked by Wall St. Rank hold CHRS as of Q1 2020.

A.R.T. Advisors reported no remaining Coherus Oncology position as of Q1 2020 after selling out during the quarter.
A.R.T. Advisors sold 83,343 Coherus Oncology shares in Q1 2020, an estimated $1.5M.
A.R.T. Advisors first reported a position in Coherus Oncology in Q3 2016 and held it in 10 quarters.
A.R.T. Advisors's Coherus Oncology position peaked at $1.98M in Q2 2019.
186 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.